R. Newton

Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics

V. Sasseville, T. Maclachlan, M. Milton, 2017, Regulatory toxicology and pharmacology : RTP.

Plasma and salivary pharmacokinetics of caffeine in man

M. Lind, H. Rogers, I. Bradbrook, 2004, European Journal of Clinical Pharmacology.

A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.

D. Rice, Byron Li, R. Stacy, 2018, Investigative ophthalmology & visual science.

Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.

Karen Anderson, Anna Vulpetti, Ulrich Hommel, 2017, Journal of medicinal chemistry.

Safety, tolerability, and pharmacokinetics of remacemide in children.

F. Besag, G. Blakey, R. Newton, 2001, Pediatric Neurology.

A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.

Yunsheng He, C. Grosskreutz, J. Peace, 2018, American journal of ophthalmology.

A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.

D. Rice, Byron Li, R. Stacy, 2018, Investigative ophthalmology & visual science.